EP3324990A4 - IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY - Google Patents

IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY Download PDF

Info

Publication number
EP3324990A4
EP3324990A4 EP16828163.2A EP16828163A EP3324990A4 EP 3324990 A4 EP3324990 A4 EP 3324990A4 EP 16828163 A EP16828163 A EP 16828163A EP 3324990 A4 EP3324990 A4 EP 3324990A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapy
peptides
identification
major histocompatibility
histocompatibility complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16828163.2A
Other languages
German (de)
French (fr)
Other versions
EP3324990A1 (en
Inventor
Gary K. Koski
Brian J. Czerniecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRIAN J. CZERNIECKI
Original Assignee
Brian J Czerniecki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/041034 external-priority patent/WO2016011432A2/en
Application filed by Brian J Czerniecki filed Critical Brian J Czerniecki
Publication of EP3324990A1 publication Critical patent/EP3324990A1/en
Publication of EP3324990A4 publication Critical patent/EP3324990A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
EP16828163.2A 2015-07-17 2016-04-07 IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY Withdrawn EP3324990A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2015/041034 WO2016011432A2 (en) 2014-07-17 2015-07-17 Identification of immunogenic mhc class ii peptides for immune-based therapy
PCT/US2016/021042 WO2017014810A1 (en) 2015-07-17 2016-03-04 Identification of immunogenic mhc class ii peptides for immune-based therapy
PCT/US2016/026542 WO2017014816A1 (en) 2015-07-17 2016-04-07 Identification of immunogenic mhc class ii peptides for immune-based therapy

Publications (2)

Publication Number Publication Date
EP3324990A1 EP3324990A1 (en) 2018-05-30
EP3324990A4 true EP3324990A4 (en) 2019-04-03

Family

ID=57835029

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16828158.2A Withdrawn EP3325005A4 (en) 2015-07-17 2016-03-04 IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY
EP16828163.2A Withdrawn EP3324990A4 (en) 2015-07-17 2016-04-07 IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP16828158.2A Withdrawn EP3325005A4 (en) 2015-07-17 2016-03-04 IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY

Country Status (5)

Country Link
EP (2) EP3325005A4 (en)
JP (3) JP2018527286A (en)
CN (1) CN107206045A (en)
CA (2) CA2992925A1 (en)
WO (2) WO2017014810A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992925A1 (en) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2021051066A1 (en) * 2019-09-13 2021-03-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. Her3 pulsed dc1 therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011343A1 (en) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Her3 peptides and dendritic cell vaccines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
CA2480099C (en) * 2002-03-26 2019-01-08 Zensun (Shanghai) Sci-Tech. Ltd. Erbb3 based methods and compositions for treating neoplasms
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
EP2049568A2 (en) * 2006-04-07 2009-04-22 Københavns Universitet Erbb receptor-derived peptide fragments
CN101500603A (en) * 2006-06-15 2009-08-05 诺华有限公司 Adjuvant-sparing multi-dose influenza vaccination regimen
CA2753119A1 (en) * 2009-02-24 2010-09-02 F. Hoffmann-La Roche Ag Use of s-erbb-3 as a marker for cancer
JP2010200693A (en) * 2009-03-04 2010-09-16 Chiyoda Kako Kensetsu Kk Culture device for producing dendritic cell vaccine and method for producing the dendritic cell
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
AU2010278702C1 (en) * 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
JP2013522309A (en) * 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア System and method for preparing and storing activated mature dendritic cells
US9127065B2 (en) * 2011-05-19 2015-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-human HER3 antibodies and uses thereof
CN108341873B (en) * 2011-12-05 2022-03-25 诺华股份有限公司 Antibodies to epidermal growth factor receptor 3(HER3)
AU2014324478A1 (en) * 2013-09-30 2016-05-05 Amgen, Inc. Nucleic acid biomarker and use thereof
CA2992925A1 (en) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification of immunogenic mhc class ii peptides for immune-based therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011343A1 (en) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Her3 peptides and dendritic cell vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATTA JASHODEEP ET AL: "Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration", ONCOIMMUNOLOGY, LANDES BIOSCIENCE, US, vol. 4, no. 10, 1 April 2015 (2015-04-01), XP002782236, ISSN: 2162-402X, DOI: 10.1080/2162402X.2015.1022301 *
FRACOL MEGAN ET AL: "Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes", ANNALS OF SURGICAL ONCOLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 24, no. 2, 23 September 2016 (2016-09-23), pages 407 - 417, XP036125796, ISSN: 1068-9265, [retrieved on 20160923], DOI: 10.1245/S10434-016-5584-6 *
JASHODEEP DATTA ET AL: "Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer : Role for Immune Monitoring", JAMA ONCOLOGY, vol. 2, no. 2, 1 February 2016 (2016-02-01), US, pages 242, XP055556159, ISSN: 2374-2437, DOI: 10.1001/jamaoncol.2015.5482 *
See also references of WO2017014816A1 *

Also Published As

Publication number Publication date
JP2018527286A (en) 2018-09-20
WO2017014816A1 (en) 2017-01-26
JP2018521953A (en) 2018-08-09
CN107206045A (en) 2017-09-26
WO2017014810A1 (en) 2017-01-26
CA2992937A1 (en) 2017-01-26
JP2021043204A (en) 2021-03-18
EP3325005A4 (en) 2019-03-27
EP3325005A1 (en) 2018-05-30
CA2992925A1 (en) 2017-01-26
EP3324990A1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
IL285403A (en) Polypeptides that remove an epitope for mhc of group i
EP3383418A4 (en) SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
EP3423044A4 (en) NANOVACCIN ACTIVANT STING FOR IMMUNOTHERAPY
IL263896A (en) T-cell preparations for immunotherapy
IL256922A (en) Pd-l1 (" programmed death-ligand 1" ) antibodies
EP3347026A4 (en) GENETIC MODIFICATION OF MACROPHAGES FOR IMMUNOTHERAPY
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
EP3645569A4 (en) IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
EP3373970A4 (en) NKG2D-IG FUSION PROTEIN FOR IMMUNOTHERAPY AGAINST CANCER
EP3493827A4 (en) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
EP3390429A4 (en) MODIFIED CAPSIDIC PROTEINS FOR ENHANCED RELEASE OF PARVOVIRAL VECTORS
EP3402517A4 (en) IMMUNOTHERAPY OF CANCER
EP3458756A4 (en) FLANGE ADAPTER
HUE053239T2 (en) Humanized tau antibodies for the treatment of Alzheimer's disease
EP3419674A4 (en) IMMUNOTHERAPY TARGETING AMYLOIDOSIS
GB201511191D0 (en) T-cell epitopes for the immunotherapy of myeloma
EP3294165A4 (en) METHODS FOR IMPLANTATION OF BONE SCREW
DK2968485T3 (en) Peptide vaccine for the prevention and immunotherapy of Alzheimer's dementia
EP3379317A4 (en) IMAGING LENS
EP3291722A4 (en) IMPROVED LENS REFRACTOR
FR3017658B1 (en) EQUIPMENT DRIVE HOUSING FOR TURBOMACHINE
EP3519028A4 (en) HARNESS FOR HARNESS
EP3347098A4 (en) TARGETING MDA-5 ACTIVATION FOR CANCER IMMUNOTHERAPY
FR3056552B1 (en) EXTERNAL ANCHORING HARPOON FOR AIRCRAFT
EP3463420A4 (en) PEPTIDES FOR HAIR GROWTH

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRIAN J. CZERNIECKI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CZERNIECKI, BRIAN J.

Inventor name: KOSKI, GARY K.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190301

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 2/00 20060101ALI20190225BHEP

Ipc: A61K 38/16 20060101ALI20190225BHEP

Ipc: G01N 33/574 20060101ALI20190225BHEP

Ipc: G01N 33/569 20060101ALI20190225BHEP

Ipc: A61K 38/00 20060101ALI20190225BHEP

Ipc: A61K 39/00 20060101AFI20190225BHEP

Ipc: C07K 16/28 20060101ALI20190225BHEP

Ipc: A61P 35/00 20060101ALI20190225BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211103